prikaz prve stranice dokumenta Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study
  Download
PDF 3.02 MB
Scientific paper - Original scientific paper
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study
American Journal of Hematology, 95 (2020), 7; 749-758. https://doi.org/10.1002/ajh.25795
Baron, Frédéric; Efficace, Fabio; Cannella, Laura; Muus, Petra; Trisolini, Silvia; Halkes, Constantijn J. M.; Fazi, Paola; Vignetti, Marco; Marie, Jean‐Pierre; Chiusolo, Patrizia; Velden, Walter; La Sala, Edoardo; Vitolo, Umberto; Thomas, Xavier; Lefrère, Francois; Di Raimondo, Francesco; Bourhis, Jean‐Henri; Specchia, Giorgina; Guimarães, José E.; Allione, Bernardino; Vrhovac, Radovan; Ferrara, Felicetto; Stevens‐Kroef, Marian; Meert, Liv; Witte, Theo; Willemze, Roelof; Amadori, Sergio; Suciu, Stefan More authors...

Cite this document

Baron, F., Efficace, F., Cannella, L., Muus, P., Trisolini, S., Halkes, C. J. M. ... Suciu, S. (2020). Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study. American Journal of Hematology, 95. (7), 749-758. doi: 10.1002/ajh.25795

Baron, Frédéric, et al. "Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study." American Journal of Hematology, vol. 95, no. 7, 2020, pp. 749-758. https://doi.org/10.1002/ajh.25795

Baron, Frédéric, Fabio Efficace, Laura Cannella, Petra Muus, Silvia Trisolini, Constantijn J. M. Halkes, Paola Fazi, et al. "Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study." American Journal of Hematology 95, no. 7 (2020): 749-758. https://doi.org/10.1002/ajh.25795

Baron, F., et al. (2020) 'Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study', American Journal of Hematology, 95(7), pp. 749-758. doi: 10.1002/ajh.25795

Baron F, Efficace F, Cannella L, Muus P, Trisolini S, Halkes CJM, and sur.. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study. American Journal of Hematology [Internet]. 2020 July [cited 2024 April 22];95(7):749-758. doi: 10.1002/ajh.25795

F. Baron, et al., "Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study", American Journal of Hematology, vol. 95, no. 7, pp. 749-758, July 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:157213. [Accessed: 22 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase study
AuthorFrédéric Baron
AuthorFabio Efficace
AuthorLaura Cannella
AuthorPetra Muus
AuthorSilvia Trisolini
AuthorConstantijn J. M. Halkes
AuthorPaola Fazi
AuthorMarco Vignetti
AuthorJean‐Pierre Marie
AuthorPatrizia Chiusolo
AuthorWalter Velden
AuthorEdoardo La Sala
AuthorUmberto Vitolo
AuthorXavier Thomas
AuthorFrancois Lefrère
AuthorFrancesco Di Raimondo
AuthorJean‐Henri Bourhis
AuthorGiorgina Specchia
AuthorJosé E. Guimarães
AuthorBernardino Allione
AuthorRadovan Vrhovac
AuthorFelicetto Ferrara
AuthorMarian Stevens‐Kroef
AuthorLiv Meert
AuthorTheo Witte
AuthorRoelof Willemze
AuthorSergio Amadori
AuthorStefan Suciu
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m2 ), mitoxantrone (MXR, 12 mg/m2 ), or idarubicin (IDA, 10 mg/m2 ) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleAmerican Journal of Hematology
Numberingvol. 95, no. 7, pp. 749-758
p-ISSN0361-8609
e-ISSN1096-8652
DOIhttps://doi.org/10.1002/ajh.25795
URN:NBNurn:nbn:hr:105:157213
Publication2020-07
Document URLhttps://onlinelibrary.wiley.com/doi/10.1002/ajh.25795
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-02-04 08:45:01